CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

Stock Information for Q32 Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Q32 Bio Inc.

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025
CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.